The alteration of NBM and LC integrity in suspected LATE argues for clinical trials evaluating the effects of cholinergic/noradrenergic treatments in progressive amnesia due to limbic TDP-43 pathology, for which no therapeutic option is currently recommended. This evidence concerns the gene TARDBP and amnesia.